BioCorRx (OTC:BICX) said today that it inked a confidentiality agreement with the National Institute on Drug Abuse, which will allow the group to share information and potentially work together on R&D and commercialization of BioCorRx’s therapies for opioid use disorder.
The National Institutes of Health division has also agreed to participate as an observer at the FDA’s pre-IND meeting for BioCorRx’s naltrexone implant slated to take place on Jan. 24.
Get the full story at our sister site, Drug Delivery Business News.
The post BioCorRx inks deal with Nat’l Institute on Drug Abuse appeared first on MassDevice.